1Julian W and Vardhan. The problem of diabetic nephropathy and practical prevention of its progression[J]. Vascular Disease,2008,8:272 - 277.
2Ascic B and Kacila M. Effects of aggressive approach to the multiple risk factors for diabetic nephropathy on proteinuria reduction in diabetes type 2 patients[J]. Basic Med Sci,2009, 9:44 - 48.
3Susumu O, Takefumi M, Kazuhiro N, et al. Angiotensin II Type 1 Receptor Blockers Reduce UrinaryOxidative Stress Markers in Hypertensive[J]. Hypertension,2006,47:699- 705.
5Sandra Beer Xenia Moren,Juan Ruiz Richard W. James. Postprandial modulation of serum paraoxonase activity and concentration in diabetic and non- diabetic subjects[J]. Nutr Metab Cardiovase Dis,2006,16(7):457- 465.
二级参考文献13
1Maron D J, Fazio S, Linton M F. Current perspectives on statins[J].Circulation,2000,101:207-213.
2American Diabetes Association. Management of dyslipidemia in adults with diabetes (Position Statement)[J].Diabetes Care,1999,22(suppl 1):s56-s59.
3Heusinger-Ribeiro J, Wahab N, Goppelt-Struebe M. Lysophosphatidic acid-induced expression of connective tissue growth factor in human renal fibrosis: regulatory role of RhoA and cAMP[J].J Am Soc Nephrol,2001,12:1853-1861.
4Massy Z A, Kim Y, Guijarro C, et al. Low-density lipoprotein-induced expression of interleukin-6, a marker of human mesangial cell inflammation: effects of oxidation and modulation by lovastatin[J].Biochem Biophys Res Commun,2000,267:536-540.
5Kim S L, Han D C, Lee H B. Lovastatin inhibits transforming growth factor-β1 expression in diabetic rat glomeruli and cultured rat mesangial cells[J].J Am Soc Nephrol,2000,11:80-87.
6Yang T, Chen J W, Liu C P. Combination of simvastatin and cilazapril have preventive effect on diabetic nephropathy in diabetic rat and cultured mesangial cells[J].Diabetologia,2001,44(supp1):A265.
7Essig M, Vrtosnik F, Nguyen G, et al. Lovastatin modulates in vivo and in vitro the plasminogen activator/plasmin system of rat proximal tubular cells: Role of geranylgeranylation and Rho proteins[J].J Am Soc Nephrol,1998,9:1377-1388.
8Liu C, Yang T, Chen J W, et al. Lovastatin inhibit insulin-like growth factor-1 expression on cultured mesangial cells[J].Diabetologia,2001,44(supp 1):A264.
9Struebe G,Hahn A, Iwanciw D, et al. Regulation of connective tissue growth factor (ccn2; ctgf) gene expression in human mesangial cells: modulation by HMG CoA reductase inhibitors (statins)[J].J Clin Pathol: Mol Pathol,2001,54:176-179.
10Riessen R, Axel D I, Fenchel M, et al. Effect of HMG-CoA reductase inhibitors on extracellular matrix expression in human vascular smooth muscle cells[J].Basic Res Cardiol,1999,94:322-332.
4Vidt DG. Inflammation in renal disease [J]. Am J Cardiol,2006,97 (2A) :20A-27A.
5Inman SR, Stowe NT, Cressman MD, et al. Lovastatin preserves renal function in experimental diabetes [ J]. Am J Med Sci, 1999, 317(4) :215-221.
6陆再英,钟南山.内科学[M].7版.北京:人民卫生出版社,2008:775.
7Barzilay JI, Abraham L, Heckbert SR, et al. The relation of markers of inflammation to the development of glucose disorders in the elder- ly : the Cardiovascular Health study. Diabetes,2001,50 (10) : 2384- 2389.
8Danesh FR, Sadeghi MM, Amro N, et al. 3-Hydroxy-5-methylglutaryl CoA reductase inhibitors prevent high glucose-induced proliferation of mesangial cells via modulation of Rho GTPase/ p21 signaling pathway:Implications for diabetic nephropathy. Proc Natl Aead Sci USA ,2002,99( 12 ) :8301-8305.
9Mogensen C E. Management of early nephropathy in dia- betic patients[ J]. Annu Rev Med, 1995,46:79-93.
10Hollenberg N K, Parving H H, Viberti G, et al. Albumi- nuria response to very high-dose valsartan in type 2 diabe- tes mellitus [ J ]. Hypertens, 2007,25 ( 9 ) : 1921-1926.
